Phase II data on Lp(a) lowering, followed by NHLBI recommendation
Lp(a) meeting Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide in CVD and presents NHLBI recommendations on Lp(a) lowering.
This lecture by Sam Tsimikas was part of the EAS-endorsed satellite meeting "The imminent danger of Lp(a): Time to face the challenge" held prior to the 87th EAS congress in Maastricht
Sam Tsimikas, Professor of Medicine and Director of Vascular Medicine at the University of California San Diego School of Medicine, San Diego, CA, USA
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: